T he Food and Drug Administration (FDA) declined on Friday to approve MDMA-assisted psychotherapy as a treatment for ...

Opinions expressed by Forbes Contributors are their own. I write about cannabis business and culture. PTSD is a serious medical condition that affects 13 million Americans any given year, or about ...

For the wider therapeutic area, the FDA’s response will act as both a cause for concern and a potential way forward. Those ...

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the ...

Lykos will ask FDA to reconsider its decision following rejection of MDMA therapy for post-traumatic stress disorder The knock-back from the FDA wasn’t the only shock to rock Lykos in recent months.

The VA may fund a new Phase III trial for MDMA therapy to treat PTSD after the FDA rejected Lykos Therapeutics' initial ...

Ecstasy, also known by the pharmaceutical shorthand MDMA (an abbreviation of 3,4-methylenedioxymethamphetamine), is used illegally by millions in the U.S. The synthetic drug has been banned since ...

and patients had pinned their hopes on the psychedelic drug midomafetamine with assisted therapy (MDMA-AT). However, in August, the US Food and Drug Administration (FDA) rejected it. At this point ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug ...

This gathering came shortly after the FDA’s decision to decline Lykos Therapeutics' application for midomafetamine ...

Area researchers are helping investigate the promise and the perils of psychedelic drugs as public interest grows.